Does Cigna Cover Vyleesi (Bremelanotide)?

How Cigna Classifies Vyleesi on Its Formulary

Cigna places Vyleesi (bremelanotide 1.75 mg subcutaneous autoinjector) on its specialty formulary tier for most commercial PPO and HMO plans. This means higher out-of-pocket costs compared to generics or preferred brands, and it triggers mandatory prior authorization before your pharmacy can fill the prescription.

Specialty Tier Placement and Cost Sharing

On a typical Cigna specialty tier, members pay a coinsurance percentage (often 25% to 33%) rather than a flat copay. At a list price near $1,200 per month, that translates to $300 to $400 monthly out-of-pocket before any savings programs. Some Cigna plans cap specialty copays, which can reduce this figure. Your specific Summary of Benefits and Coverage document will list the exact coinsurance rate.

Why Formulary Tier Matters

Tier placement affects more than cost. Specialty-tier drugs on Cigna plans typically require dispensing through Cigna's preferred specialty pharmacy (often Accredo or Express Scripts Specialty). You may not be able to fill Vyleesi at a retail pharmacy. Confirm your plan's specialty pharmacy network before your prescriber submits the authorization request.

Checking Your Specific Plan

Cigna operates hundreds of plan variants. Employer-sponsored plans can customize formularies and coverage criteria independently. The most reliable way to verify your tier and cost sharing is to log into myCigna.com, search the drug formulary tool for "bremelanotide" or "Vyleesi," and review the coverage details specific to your plan ID.

Prior Authorization Criteria for Vyleesi on Cigna

Cigna requires prior authorization (PA) for Vyleesi, and the approval criteria follow a predictable clinical pattern. Your prescriber will need to document several items before Cigna will approve.

Clinical Documentation Cigna Expects

The PA request typically must confirm the patient is a premenopausal woman with a diagnosis of HSDD (ICD-10 code F52.0) that is not explained by a coexisting medical condition, psychiatric disorder, relationship problem, or medication side effect. The FDA approved bremelanotide specifically for generalized HSDD in premenopausal women based on the RECONNECT trials, and Cigna's criteria mirror this label closely.

Cigna commonly requires documentation that the patient has:

• A confirmed HSDD diagnosis using a validated screening tool such as the Decreased Sexual Desire Screener (DSDS)
• No contraindicated cardiovascular conditions (uncontrolled hypertension is a labeled contraindication)
• Tried or been evaluated for contributing factors like SSRIs, hormonal changes, or relationship-based causes

Step Therapy Requirements

Some Cigna plans impose step therapy, requiring a trial of flibanserin (Addyi) before approving Vyleesi. This is not universal across all Cigna plans, but it is common enough that prescribers should address it proactively. If your patient tried flibanserin and discontinued due to side effects (somnolence, dizziness, or the alcohol interaction restriction), document that clearly in the PA submission. Cigna will generally accept a documented flibanserin failure or intolerance as meeting the step therapy requirement.

Timeline for PA Decisions

Cigna must respond to a standard PA request within 15 calendar days under most state regulations. Urgent or expedited requests (when delay could seriously jeopardize health) require a response within 72 hours. If your prescriber's office has not heard back within these windows, they should call Cigna's provider services line directly.

What the RECONNECT Trials Showed About Bremelanotide

The FDA approved bremelanotide in June 2019 based primarily on two Phase 3 trials known as RECONNECT 1 and RECONNECT 2. These trials enrolled 1,247 premenopausal women with HSDD and measured changes in sexual desire and distress over 24 weeks.

Efficacy Results

In the pooled RECONNECT analysis, women using bremelanotide 1.75 mg subcutaneously as needed showed a statistically significant improvement in the Female Sexual Function Index (FSFI) desire domain score compared to placebo. The co-primary endpoint of the Female Sexual Distress Scale (FSDS-DAO) Item 13 (distress about low desire) also improved significantly. The mean change from baseline in FSFI desire domain was approximately 0.5 points greater with bremelanotide versus placebo. That may look modest in isolation, but the distress reduction was clinically meaningful to patients. About 35% of bremelanotide-treated women reported meaningful improvement in desire versus 31% on placebo.

Safety Profile

Nausea was the most common adverse event, reported in roughly 40% of bremelanotide-treated patients versus 1% on placebo. Most nausea was mild to moderate and decreased with repeated dosing. The FDA label includes a warning about transient blood pressure increases (averaging 2 to 3 mmHg systolic) after injection, which is why the drug is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

Why This Matters for Cigna Approval

Cigna's medical reviewers evaluate PA requests against published efficacy data. The RECONNECT results are the primary evidence base. If a PA is denied on medical necessity grounds, citing these specific trial results in your appeal strengthens the case. A denial that ignores published Phase 3 data is vulnerable on appeal.

How to Appeal a Cigna Denial of Vyleesi

If Cigna denies your Vyleesi prior authorization, you have a structured appeal pathway. Do not accept a denial as final. The multi-level process exists specifically because initial denials are often reversed.

Level 1: First Internal Appeal

You or your prescriber must file the first appeal within 180 days of the denial notice. Include the denial letter, a letter of medical necessity from the prescribing physician, relevant chart notes confirming the HSDD diagnosis, documentation of any step therapy failures, and citations to the RECONNECT trial data. Cigna must respond within 30 days for a standard appeal or 72 hours for an expedited appeal.

Level 2: Second Internal Appeal

If the first appeal is denied, Cigna offers a second internal review. A different medical reviewer (one who was not involved in the original decision or first appeal) evaluates the case. Submit any additional clinical documentation, including specialist consultation notes if available. A letter from a sexual medicine specialist carries weight at this level.

External Independent Review

After exhausting both internal appeals, you can request an external review by an independent review organization (IRO). This is a right guaranteed under the Affordable Care Act's external review provisions. The IRO is not employed by Cigna and renders a binding decision. External review reversal rates for specialty drugs vary, but they provide a genuinely independent evaluation.

Practical Tips for a Successful Appeal

Keep copies of every submission. Use certified mail or electronic confirmation. Include the specific ICD-10 code (F52.0), the National Drug Code for Vyleesi, and reference the FDA-approved indication. If your prescriber can document that the patient meets every criterion in Cigna's own published coverage policy and was still denied, state that explicitly. Inconsistency between a plan's own policy and its denial decision is one of the strongest grounds for reversal.

Using the Manufacturer Savings Card With Cigna

AMAG Pharmaceuticals (now Covis Pharma) offers a manufacturer savings card for Vyleesi that can reduce out-of-pocket costs for commercially insured patients. The card typically covers a portion of the copay or coinsurance after insurance processes the claim.

Eligibility Requirements

The savings card is available to patients with commercial insurance, including Cigna commercial plans. Patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs are not eligible. The card has an annual maximum benefit (often $6,000 to $9,000 per year, though terms change periodically), and it applies only to the patient's cost-sharing obligation after Cigna processes the claim.

How It Works With Specialty Pharmacy

Because Cigna often routes Vyleesi through a specialty pharmacy, you will need to provide the savings card information to that pharmacy (not a retail pharmacy). Call the number on the savings card to confirm it can be applied at your Cigna-designated specialty pharmacy. Some specialty pharmacies apply manufacturer cards automatically once they are on file. Others require the patient to request application at each fill.

Accumulator Adjustment Programs

One important caution: some Cigna plans use copay accumulator adjustment programs. Under these programs, manufacturer copay card payments do not count toward your annual deductible or out-of-pocket maximum. This means you could exhaust the savings card benefit and still face the full remaining deductible. Check your Cigna plan documents for language about "accumulator adjustment" or "copay maximizer" programs. If your plan uses one, factor that into your annual cost projections.

Vyleesi Coverage for Off-Label Uses on Cigna

Cigna covers Vyleesi only for its FDA-approved indication: HSDD in premenopausal women. Off-label requests face a near-certain denial.

Weight Loss Claims

Bremelanotide acts on melanocortin receptors (specifically MC4R), and preclinical research has explored melanocortin pathway activation in energy homeostasis and appetite regulation. Cigna does not cover Vyleesi for weight loss. No clinical trial has demonstrated efficacy of bremelanotide at its approved dose for weight management in humans. The RECONNECT trials did not report significant weight changes as an outcome. Any social media claims about Vyleesi for weight loss are not supported by published evidence, and Cigna will deny such requests.

Postmenopausal HSDD

The FDA approval is limited to premenopausal women. Cigna will deny PA requests for postmenopausal patients. While some clinicians prescribe bremelanotide off-label in this population, insurance coverage for off-label use requires compendia support (such as listing in DRUGDEX or AHFS-DI), which bremelanotide currently lacks for postmenopausal HSDD.

Comparing Cigna Coverage: Vyleesi vs. Flibanserin

Cigna covers both FDA-approved HSDD treatments, but with different access pathways and cost profiles.

Flibanserin (Addyi)

Flibanserin is an oral tablet taken daily at bedtime. It is typically placed on a lower formulary tier than Vyleesi on Cigna plans, with lower copays. Cigna generally does not require step therapy before flibanserin (since it is often the step therapy drug itself). The FDA label for flibanserin carries a boxed warning about hypotension and syncope with alcohol, and prescribers must complete a REMS certification.

Key Differences for Cigna Members

Vyleesi is used as needed (up to 8 doses per month), while flibanserin requires daily dosing. Some patients prefer the as-needed model because they do not want to take a daily medication for a condition that affects them intermittently. From a Cigna formulary perspective, flibanserin's lower tier placement and the absence of step therapy make it the path of least resistance for initial coverage. Patients who fail or cannot tolerate flibanserin then have a clear basis for Vyleesi authorization.

The nausea rate with bremelanotide (approximately 40% in RECONNECT) is substantially higher than with flibanserin (approximately 10% in the BEGONIA and DAISY trials), but flibanserin's alcohol restriction and daily dosing are barriers for many patients. These clinical tradeoffs should be documented in the PA submission if Cigna requires justification for choosing Vyleesi over flibanserin.

What to Do if You Have Cigna Medicare Advantage

Cigna Medicare Advantage plans may handle Vyleesi differently from commercial plans. Because bremelanotide is FDA-approved only for premenopausal women, and Medicare beneficiaries are predominantly postmenopausal, coverage requests through Medicare Advantage are uncommon and typically denied on indication grounds. Premenopausal women on Medicare Advantage due to disability may have a pathway, but should expect a coverage determination request and likely an appeal.

Medicare Part D formularies are published annually. Search Medicare.gov's plan finder tool with the drug name to check whether your specific Cigna Medicare Advantage plan lists Vyleesi.